Multi-Targeted Anti-Cancer Mechanisms of Li-Ginseng Powder in Colitis-Associated Colorectal Cancer: Integrating Inflammation, Apoptosis and Immunity

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

The incidence of colitis-associated colorectal cancer (CAC) is increasing, while conventional single-target therapies often demonstrate limited efficacy and long-term adverse effects. As a result, multi-target natural compounds have emerged as promising alternatives. This study investigates the anti-CAC potential of Li-Ginseng Powder (LGP), a specially processed functional food derived from Panax ginseng and enriched with rare ginsenosides (Rk1, Rk3, Rh4, Rg3, and Rg5), demonstrates strong preventive potential and characterized by minimal toxicity. Multi-omics analyses revealed that CAC model mice exhibited key tumor-promoting features, including heightened inflammation, impaired apoptosis, and immune suppression. Notably, LGP displayed significant anti-CAC activity and reversed 98.14% of dysregulated protein expression (fold-change > 1.5, p  < 0.05). It effectively mitigated inflammation by inhibiting STAT3/NF-κB signaling and modulating inflammatory gene expression. LGP induced apoptosis by downregulating anti-apoptotic proteins (Bcl-2, Bcl-XL, and x-IAP), upregulating pro-apoptotic Bax and Granzyme B, and promoting PARP and Caspase-9 cleavage to facilitate the elimination of damaged cells. Moreover, it enhanced immune responses by increasing NK cell and CD3 + T cell infiltration while activating CD4 + and CD8 + T cells. Additionally, LGP modulated serum metabolites and gut microbiota composition, fostering a favorable disease trajectory. These findings elucidate LGP’s comprehensive anti-CAC mechanism, integrating inflammation suppression, apoptosis induction, immune modulation, and microbiota regulation. This study addresses a critical gap in ginseng-derived CAC therapies, offering a promising multi-targeted and low-risk therapeutic strategy for clinical application.

Article activity feed